By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Prothena Corporation plc 

25-28 North Wall Quay

  Dublin  1  Ireland
Phone: 353-1-902-3519 Fax: 353-1-902-3510


SEARCH JOBS


Industry
Biotechnology






Company News
Prothena (PRTA) Announces Addition Of Seasoned Executive To Board Of Directors 6/30/2015 7:34:22 AM
Prothena (PRTA) To Present At JMP Securities Life Science Conference 2015 On June 23 6/17/2015 8:39:06 AM
Prothena (PRTA) Presents Clinical Results Demonstrating Robust, Rapid Reduction In Levels Of Free Serum Alpha-Synuclein Of Up To 96% After Single Dose Of PRX002, Novel Protein Immunotherapy For Parkinson's Disease 6/17/2015 7:10:47 AM
Prothena (PRTA) Release: Opportunity To Improve Diagnosis And Treatment Of Systemic Amyloidosis Highlighted In Patient Experience Survey Presented At The 20th Congress Of The European Hematology Association 6/12/2015 7:48:03 AM
Prothena (PRTA)'s NEOD001 Protein Immunotherapy Clinical Data Highlighted In Oral Presentation At The 20th Congress Of The European Hematology Association 6/12/2015 7:17:34 AM
Prothena (PRTA) Announces First Human Dosed In Phase I Study Of PRX003 For The Treatment Of Psoriasis And Other Inflammatory Diseases 6/10/2015 7:17:58 AM
Prothena (PRTA) To Present Clinical Results From Its Phase I Single Ascending Dose Study Of PRX002 At 19th International Congress Of Parkinson's Disease And Movement Disorders 6/8/2015 11:35:44 AM
ASCO15: Prothena (PRTA) Presents Compelling New Data From Ongoing Phase I/II Study Of NEOD001 In Patients With AL Amyloidosis At 2015 ASCO Annual Meeting 6/2/2015 10:37:45 AM
Prothena (PRTA) Announces Presentation Of Clinical Data From The Ongoing Phase I/II NEOD001 Study And Systemic Amyloidosis Patient Survey Results At 20th Congress Of The European Hematology Association 5/21/2015 1:32:31 PM
Prothena (PRTA) To Present Updated Clinical Data From Ongoing Phase I/II Study Of NEOD001 At 2015 ASCO Annual Meeting 5/14/2015 7:31:30 AM
123456
//-->